In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Leans on Vardenafil

Executive Summary

Dubbed "the new blockbuster" by Bayer AG management, the PDE5 inhibitor vardenafil is by most accounts more potent, faster acting, and less prone to side effects than its pharmaceutical cousin, Pfizer Inc.'s sildenafil (Viagra). But vardenafil's potential-and its role as a potential savior of Bayer's ailing pharmaceuticals division-may be overshadowed by the chinks that this same promise has helped expose in the Bayer armor.

You may also be interested in...



Organon Kicks Off Partnering Strategy with Pfizer Deal

Hard times at drug division Organon have forced Akzo Nobel to cut costs and restructure. As part of this effort, the Dutch conglomerate has implemented an aggressive partnering strategy to maximize the value of its late-stage pharma pipeline. Its potential $370 million pact with Pfizer for the Phase II/III antipsychotic asenapine marks an impressive start, and underscores Akzo's commitment to rebuilding Organon.

ED in Europe: A Rising Tide?

Worldwide launches of new PDE5 inhibitors to treat erectile dysfunction are certain to expand the global market for these and other ED therapies. But in Europe, Viagra's brand ubiquity, the prohibition of DTC advertising, and disparate national markets present challenges to firms hoping to dethrone the Pfizer juggernaut.

GW/Bayer: Sharing Value

In its late-stage licensing deal with GW Pharmaceuticals for Sativex, Bayer accepted UK-only rights, and will share the product's value equally with GW. This unusual agreement largely reflects the particular nature of the product. But it also shows that, at least in some situations, biotechs can still partner out their jewels without giving away too much value.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel